Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Hemoglobin and Genome Lab, |
RCV000496150 | SCV000586733 | likely pathogenic | Deficiency of ferroxidase | 2017-07-28 | criteria provided, single submitter | research | |
Mendelics | RCV000496150 | SCV002519432 | pathogenic | Deficiency of ferroxidase | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003226310 | SCV003922500 | likely pathogenic | Neurodegeneration with brain iron accumulation | 2023-03-10 | criteria provided, single submitter | clinical testing | Variant summary: CP c.2756T>C (p.Leu919Pro) results in a non-conservative amino acid change in the encoded protein sequence. Four of four in-silico tools predict a damaging effect of the variant on protein function. At least one computational study showed Leu919 is involved in a network of hydrophobic interactions with Leu921 and Leu808 and the substitution by a proline would probably lead to perturbations in this network, altering the stability of the protein (Vila Cuenca_2020). The variant was absent in 251254 control chromosomes (gnomAD). c.2756T>C has been reported in the literature in homozygous individuals affected with Aceruloplasminaemia (Borges_2019, Vila Cuenca_2020) and one heterozygote carrier whose serum ceruloplasmin levels were decreased, with normal ferritin and serum iron (Borges_2019). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submitters (evaluation after 2014) cite this variant as pathogenic and likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |